Volume 6; Issue 3

Main
Blood Cancer Journal
Volume 6; Issue 3

Blood Cancer Journal

Volume 6; Issue 3

1

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

Tefferi, A, Al-Kali, A, Begna, K H, Patnaik, M M, Lasho, T L, Rizo, A, Wan, Y, Hanson, C A

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 171 KB

english, 2016

2

miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia

Navarro, A, Pairet, S, Álvarez-Larrán, A, Pons, A, Ferrer, G, Longarón, R, Fernández-Rodríguez, C, Camacho, L, Monzó, M, Besses, C, Bellosillo, B

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 1.76 MB

english, 2016

3

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Bühler, A, Wendtner, C-M, Kipps, T J, Rassenti, L, Fraser, G A M, Michallet, A-S, Hillmen, P, Dürig, J, Gregory, S A, Kalaycio, M, Aurran-Schleinitz, T, Trentin, L, Gribben, J G, Chanan-Khan, A, Purse

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 431 KB

english, 2016

4

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G, Barlogie, B

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 612 KB

english, 2016

5

Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014

Laforet, M, Jourde-Chiche, N, Haddad, F, Sallee, M, Stoppa, A M, Brunet, P, Dussol, B, Burtey, S, Gondouin, B

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 231 KB

english, 2016

6

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

Binder, M, Rajkumar, S V, Ketterling, R P, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves,

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 884 KB

english, 2016

7

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

Ratner, L, Rauch, D, Abel, H, Caruso, B, Noy, A, Barta, S K, Parekh, S, Ramos, J C, Ambinder, R, Phillips, A, Harding, J, Baydoun, H H, Cheng, X, Jacobson, S

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 334 KB

english, 2016

8

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

Phillips, D C, Xiao, Y, Lam, L T, Litvinovich, E, Roberts-Rapp, L, Souers, A J, Leverson, J D

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 485 KB

english, 2016

9

Loss of RUNX1 function results in enhanced granulocyte-colony-stimulating factor-mediated mobilization

Lam, K, Muselman, A, Du, R, Yan, M, Matsuura, S, Zhang, D-E

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 358 KB

english, 2016

10

Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C

Lin, R J, Moskovits, T, Diefenbach, C S, Hymes, K B

Journal:

Blood Cancer Journal

Year:

2016

Language:

english

File:

PDF, 123 KB

english, 2016